Referencias y Abreviaturas

Referencias

  1. European Medicines Agency. Ficha técnica de Eylea®. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdf.
  2. Ophthalmologic Drugs Advisory Committee: VEGF Trap-Eye briefing document. Tarrytown, NY: Regeneron Pharmaceuticals Inc.; June 17, 2011.
  3. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-8.
  4. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A. 2007;104(47):18363-70.
  5. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-85.
  6. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434-57.
  7. European Medicines Agency. Ficha técnica de Lucentis®. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/000715/WC500043546.pdf. Último acceso: abril de2013.
  8. European Medicines Agency. Ficha técnica de Avastin®. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/000582/WC500029271.pdf. Último acceso: abril de 2013.
  9. Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1(7):1356-70.
  10. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-83.
  11. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2008;92(5):667-8.
  12. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119: 2537-48.
  13. European Medicines Agency. Eylea: EPAR – public assessment report. EMA/646256/2012 corr. September 20, 2012. Consultado en mayo de 2013. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pub¬lic_assessment_report/human/002392/WC500135744.pdf
  14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis®) for neovascular age-realted macular degeneration. Am J Ophtalmol.2007;143:566-83.
  15. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
  16. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98.
  17. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study Group. Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology. 2013;120(5):1046-56.
  18. Chakravarthy U, Harding SP, Rogers CA, et al; The IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-411.
  19. Gerding H, Loukopoulos V, Riese J, et al. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol. 2011;249(5):653-62.
  20. Monés J, Biarnés M, Trindade F, et al. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol. 2012;250(12):1737-44.
  21. Sociedad Española de Retina y Vítreo. Tratamiento de la Degeneracion Macular Asociada a la Edad (DMAE) Exudativa. Guías de Práctica Clínica de la SERV. Disponible en www.serv.es. Último acceso: junio de 2013.
  22. Lanzetta P, Mitchell P, Wolf S, et al. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Br J Ophthamol. 2013; 97(12): 1497-507.
  23. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six-Week Results of the VIEW Studies. Ophthalmology. 2014;121(1):193-201.
  24. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-32.
  25. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278-84.
  26. Korobeinick JF, Holz FG, Roider J, et al. Intravitreal aflibercept inyection for macular edema due to central retinal vein occlusion 1-year results of the phase 3 GALILEO study. Ophthalmology. 2013 Sep 28. pii:S0161-6420(13)00730-6.
  27. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept inyection for macular edema secondary to central retinal vein occlusion 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429-37.
  28. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal afl ibercept for diabetic macular edema. 2014;121(11):2247-54.
  29. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116(3):461-7.
  30. Brown DM. Intravitreal afl ibercept injection for diabetic macular edema. Oral presentation presented at: the 2014 Association for Research in Vision and Ophthalmology Annual Meeting. May 4-8, 2014; Orlando, Florida.
  31. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-52.
  32. Marcus DM. Long-term follow-up of intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD) in an open-label extension of the VIEW 1 study. Presentado en: The Association for Research in Vision and Ophthalmology Annual Meeting; 4.8 Mayo, 2014; Orlando, Florida. C0245.
  33. Korobelnik J-F, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: 1-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121(1):202-8.
  34. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-44.

Abreviaturas

  • AV: Agudeza Visual
  • DE: Desviación Estándar
  • DMAE: Degeneración Macular Asociada a la Edad
  • EMD: Edema Macular Diabético
  • ETDRS: Early Treatment Diabetic Retinopathy Study
  • FA: Angiografía con Fluoresceína
  • GRC: Grosor Retiniano Central
  • IgG1: Inmunoglobulina G1
  • MAVC: Mejor Agudeza Visual Corregida
  • NVC: Neovascularización Coroidea
  • OCT: Tomografía de Coherencia Óptica
  • OVCR / ORVR: Oclusión de la Vena Central Retiniana
  • PRN: Tratamiento a “demanda” (Pro Re Nata)
  • PIGF: Factor de Crecimiento Placentario (en inglés, Placental Growth Factor)
  • VEGF: Factor de Crecimiento Endotelial Vascular (en inglés, Vascular Endothelial Growth Factor)
  • VEGFR: Receptor del Factor de Crecimiento Endotelial Vascular (en inglés, Vascular Endothelial Growth Factor Receptor)
  • VIEW: VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD




 

La información que figura en la página web está dirigida exclusivamente a Profesionales sanitarios facultados para prescribir o dispensar medicamentos.